Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial.Alexander M.M. Eggermont, Ferdy J. Lejeune, H. Schraffordt Koops et al.|Journal of Clinical Oncology|1996Cited by 401
Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593.Hs Koops, Ferdy J. Lejeune, J. Göhl et al.|Journal of Clinical Oncology|1998Cited by 246
Safety and efficacy of isolated limb perfusion in elderly melanoma patientsE.M. Noorda, B.B.R. Kroon, B. C. Vrouenraets et al.|Annals of Surgical Oncology|2002Cited by 60
Repeat isolated limb perfusion with TNFα and melphalan for recurrent limb melanoma after failure of previous perfusionE.M. Noorda, B.B.R. Kroon, Omgo E. Nieweg et al.|European Journal of Surgical Oncology|2006Cited by 46
High tPA-expression in primary melanoma of the limb correlates with good prognosisCilia M. Ferrier, D. J. Ruiter, Stefan Suciu et al.|British Journal of Cancer|2000Cited by 44